Ser472
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser472  -  Akt3 (human)

Site Information
RPHFPQFsysAsGRE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447937
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 4 ) , mass spectrometry ( 6 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ) , mutation of modification site ( 7 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 33 , 34 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 33 )
Disease tissue studied:
adrenal cancer ( 4 ) , pheochromocytoma ( 4 ) , breast cancer ( 4 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, triple negative ( 6 ) , cervical cancer ( 33 ) , lung cancer ( 11 , 19 , 22 , 23 , 24 , 27 , 28 , 30 , 31 ) , non-small cell lung cancer ( 10 , 11 , 19 , 22 , 23 , 24 , 27 , 28 , 30 , 31 ) , non-small cell lung adenocarcinoma ( 19 , 22 , 23 , 24 , 28 , 30 , 31 ) , non-small cell squamous cell lung carcinoma ( 22 , 23 , 24 , 28 , 30 , 31 ) , neuroblastoma ( 3 , 5 ) , pancreatic cancer ( 4 ) , pancreatic carcinoma ( 4 ) , melanoma skin cancer ( 26 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
APOE (human) ( 3 ) , DPCD (human) ( 1 ) , PHLPP (human) ( 5 , 32 ) , PHLPP2 (human) ( 5 , 32 ) , PIH1D1 (human) ( 1 ) , RPAP3 (human) ( 1 ) , RUVBL1 (human) ( 1 ) , RUVBL2 (human) ( 1 )
Putative upstream phosphatases:
PHLPP (human) ( 32 ) , PHLPP2 (human) ( 32 )
Treatments:
Akt-I-1 ( 33 ) , Akt-I-1,2 ( 33 ) , EGF ( 4 ) , insulin ( 4 , 5 , 34 ) , MK-2206 ( 2 ) , NGF ( 4 ) , phorbol_ester ( 4 ) , siRNA ( 32 )

Downstream Regulation
Effects of modification on Akt3:
phosphorylation ( 4 )
Effects of modification on biological processes:
carcinogenesis, induced ( 4 ) , cell growth, induced ( 4 ) , cell motility, altered ( 7 )

References 

1

Mao YQ, et al. (2024) DPCD is a regulator of R2TP in ciliogenesis initiation through Akt signaling. Cell Rep 43, 113713
38306274   Curated Info

2

Palma MS, Perez SR, Husain A, Bhandari D (2024) Substrate preference of protein kinase B isoforms can vary depending on the cell line. PLoS One 19, e0298322
38502658   Curated Info

3

Cakir Z, et al. (2023) Quantitative proteomic analysis reveals apoE4-dependent phosphorylation of the actin-regulating protein VASP. Mol Cell Proteomics, 100541
37019383   Curated Info

4

Wainstein E, Maik-Rachline G, Blenis J, Seger R (2022) AKTs do not translocate to the nucleus upon stimulation but AKT3 can constitutively signal from the nuclear envelope. Cell Rep 41, 111733
36476861   Curated Info

5

Sharma M, Dey CS (2022) PHLPP isoforms differentially regulate Akt isoforms and AS160 affecting neuronal insulin signaling and insulin resistance via Scribble. Cell Commun Signal 20, 179
36376971   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Baek ST, et al. (2015) An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development. Nat Med 21, 1445-54
26523971   Curated Info

8

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

9

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

10

Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info

11

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

12

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

13

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

14

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

15

Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

16

Mulhern D (2011) CST Curation Set: 13068; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

17

Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

18

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

19

Rikova K (2011) CST Curation Set: 10887; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

20

Guo A (2011) CST Curation Set: 11232; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS*/T*F/Y) Immunoaffinity Beads Cat#: 1992
Curated Info

21

Guo A (2011) CST Curation Set: 11234; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS*/T*F/Y) Immunoaffinity Beads Cat#: 1992
Curated Info

22

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

23

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

24

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

25

Guo A (2010) CST Curation Set: 6258; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

26

Tucker M (2010) CST Curation Set: 9780; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

27

Rikova K (2010) CST Curation Set: 9454; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

28

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

30

Possemato A (2009) CST Curation Set: 8409; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

31

Possemato A (2009) CST Curation Set: 8410; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

32

Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-31
17386267   Curated Info

33

Barnett SF, et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385, 399-408
15456405   Curated Info

34

Nakatani K, et al. (1999) Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Commun 257, 906-10
10208883   Curated Info

35

Walker KS, et al. (1998) Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem J 331 ( Pt 1), 299-308
9512493   Curated Info